ARS Pharmaceuticals (SPRY) Other Non-Current Assets (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Other Non-Current Assets of $2.7 million for Q1 2026, down 4.77% sequentially from $2.8 million in Q4 2025, and down 15.27% YoY from $3.1 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Other Non-Current Assets (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Other Non-Current Assets for 7 years, with the latest figure at $2.7 million in Q1 2026.
- Quarterly Other Non-Current Assets fell 15.27% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (down 15.27% YoY) and the FY2025 annual result came in at $2.8 million, down 10.53% from the prior year.
- Other Non-Current Assets eased to $2.7 million in Q1 2026 per SPRY's latest filing, from $2.8 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $3.1 million in Q1 2025 and troughed at $21000.0 in Q4 2023.
- A 5-year average of $2.2 million and a median of $2.8 million in 2025 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets tumbled 99.29% in 2023, then surged 14728.57% in 2024.
- Over 5 years, Other Non-Current Assets stood at $3.0 million in 2022, then sank by 99.29% to $21000.0 in 2023, then soared by 14728.57% to $3.1 million in 2024, then declined by 10.53% to $2.8 million in 2025, then retreated by 4.77% to $2.7 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $2.7 million, $2.8 million, and $2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | 2.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.96 Mn |
| Mar 31, 2026 | 2.65 Mn |
| Dec 31, 2025 | 2.79 Mn |
| Sep 30, 2025 | 2.92 Mn |
| Jun 30, 2025 | 3.05 Mn |
| Mar 31, 2025 | 3.13 Mn |
| Dec 31, 2024 | 3.11 Mn |
| Dec 31, 2023 | 21,000.00 |
| Sep 30, 2023 | 2.48 Mn |
| Mar 31, 2023 | 2.86 Mn |
| Dec 31, 2022 | 2.96 Mn |
| Sep 30, 2022 | 2.40 Mn |
| Jun 30, 2022 | 250,000.00 |
| Mar 31, 2022 | 250,000.00 |
| Dec 31, 2021 | 23,000.00 |
| Sep 30, 2021 | 350,000.00 |
| Jun 30, 2021 | 350,000.00 |
| Mar 31, 2021 | 350,000.00 |
| Dec 31, 2020 | 350,000.00 |